Drew Moghanaki, Professor, Chief of Thoracic Oncology, Department of Radiation Oncology at David Geffen School of Medicine at UCLA, shared on LinkedIn:
“It is appropriate to believe that upfront surgery might lead to better long term outcome for patients with clinical stage I lung cancer. Yet it remains unknown whether the incisions required to resect lung cancer propagate metastatic progression and lead to inferior outcomes vs upfront SBRT.
This study question is being diligently studied by the VA Cooperative Study Program’s Phase III randomized 2005 VALOR trial and will soon clarify whether one of these treatments is actually better than the other.”
This also can be interesting:
